A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100

NCT01534052 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

52

Enrollment

INDUSTRY

Sponsor class

Conditions

Castration-Resistant Prostate Cancer (CRPC)

Interventions

DRUG: Enzalutamide

Sponsor

Astellas Pharma Inc

Collaborators

[object Object]